EUELC project: a multi-centre, multipurpose study to investigate early stage NSCLC, and to establish a biobank for ongoing collaboration
暂无分享,去创建一个
Y. Martinet | P. Hainaut | E. Brambilla | K. O'Byrne | E. Smit | E. Brambilla | A. Risch | J. Timsit | G. Sozzi | A. Cassidy | J. Nikliński | T. Liloglou | M. Pajares | F. Thunnissen | C. Brambilla | L. Roz | Y. Martinet | J. Elborn | J. Vignaud | L. Montuenga | M. Lozano | J. Field | P. Snijders | J. Gosney | H. Becker | A. Vésin | C. Brambilla | A. Vesin | J. S. Elborn | J. K. Field | T. Liloglou | A. Niaz | J. Bryan | J. R. Gosney | T. Giles | J-F. Timsit | J. M. Vignaud | F. B. Thunnissen | C. Prinsen | P. J. Snijders | E. F. Smit | G. Sozzi | L. Roz | A. Risch | H. D. Becker | N. D. Magee | L. M. Montuenga | M. J. Pajares | M. D. Lozano | K. J. O'Byrne | D. J. Harrison | J. Niklinski | A. Cassidy | P. Hainaut | C. Prinsen | T. Giles | J. Bryan | A. Niaz | D. Harrison | A. Niaz | N. Magee | A. Cassidy | John K. Field | Kenneth J. O'Byrne | E. F. Smit | P. Hainaut | Gabriella Sozzi | Christian Brambilla | Elisabeth Brambilla | Julie Bryan | Yves Martinet | Frederik B.J.M. Thunnissen | Clemens F M Prinsen | P. Snijders | Angela Risch | Heinrich D. Becker | Joseph Elborn | Luis M. Montuenga | Maria D. Lozano | David J. Harrison | Jacek Nikliński
[1] Xifeng Wu,et al. Cancer diagnosis in first-degree relatives and non-small cell lung cancer risk: results from a multi-centre case-control study in Europe. , 2009, European journal of cancer.
[2] E. Brambilla,et al. Fragile histidine triad gene inactivation in lung cancer: the European Early Lung Cancer project. , 2009, American journal of respiratory and critical care medicine.
[3] Simon Heath,et al. Lung cancer susceptibility locus at 5p15.33 , 2008, Nature Genetics.
[4] Christopher I Amos,et al. Common 5p15.33 and 6p21.33 variants influence lung cancer risk , 2008, Nature Genetics.
[5] S. Duffy,et al. A global approach to cancer-screening trials. , 2008, The Lancet. Oncology.
[6] S. Lippman,et al. Lung cancer. , 2008, The New England journal of medicine.
[7] G. Mills,et al. Genome-wide association scan of tag SNPs identifies a susceptibility locus for lung cancer at 15q25.1 , 2008, Nature Genetics.
[8] Daniel F. Gudbjartsson,et al. A variant associated with nicotine dependence, lung cancer and peripheral arterial disease , 2008, Nature.
[9] Paolo Vineis,et al. A susceptibility locus for lung cancer maps to nicotinic acetylcholine receptor subunit genes on 15q25 , 2008, Nature.
[10] S. Duffy,et al. The LLP risk model: an individual risk prediction model for lung cancer , 2007, British Journal of Cancer.
[11] S. Rogers,et al. Quantitative methylation analysis of resection margins and lymph nodes in oral squamous cell carcinoma. , 2007, The British journal of oral & maxillofacial surgery.
[12] Haesook T. Kim. Cumulative Incidence in Competing Risks Data and Competing Risks Regression Analysis , 2007, Clinical Cancer Research.
[13] Gorka Bastarrika,et al. Molecular Profiling of Computed Tomography Screen-Detected Lung Nodules Shows Multiple Malignant Features , 2006, Cancer Epidemiology Biomarkers & Prevention.
[14] Pierre P Massion,et al. Novel strategies for the early detection and prevention of lung cancer. , 2005, Seminars in oncology.
[15] J. Ferlay,et al. Global Cancer Statistics, 2002 , 2005, CA: a cancer journal for clinicians.
[16] Dimitrios Iliopoulos,et al. Fragile genes as biomarkers: epigenetic control of WWOX and FHIT in lung, breast and bladder cancer , 2005, Oncogene.
[17] L. Dwyer-Nield,et al. Relative amounts of antagonistic splicing factors, hnRNP A1 and ASF/SF2, change during neoplastic lung growth: Implications for pre‐mRNA processing , 2004, Molecular carcinogenesis.
[18] S. Vicent,et al. αCP-4, Encoded by a Putative Tumor Suppressor Gene at 3p21, But Not Its Alternative Splice Variant αCP-4a, Is Underexpressed in Lung Cancer , 2004, Cancer Research.
[19] J. Berkhof,et al. Elevated hTERT mRNA levels: A potential determinant of bronchial squamous cell carcinoma (in situ) , 2004, International journal of cancer.
[20] U. Pastorino,et al. Quantification of free circulating DNA as a diagnostic marker in lung cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[21] Elisabeth Brambilla,et al. Expression of VEGF, semaphorin SEMA3F, and their common receptors neuropilins NP1 and NP2 in preinvasive bronchial lesions, lung tumours, and cell lines , 2003, The Journal of pathology.
[22] Y. Pekarsky,et al. FHIT as Tumor Suppressor: Mechanisms and Therapeutic Opportunities , 2002, Cancer biology & therapy.
[23] P. Maloney,et al. Cancer-specific genomic instability in bronchial lavage: a molecular tool for lung cancer detection. , 2001, Cancer research.
[24] F. Alla,et al. Retinoic acid receptor and retinoid X receptor alterations in lung cancer precursor lesions. , 2000, Cancer research.
[25] W. Prime,et al. Genetic alterations in bronchial lavage as a potential marker for individuals with a high risk of developing lung cancer. , 1999, Cancer research.
[26] P. Hainaut,et al. A specific spectrum of p53 mutations in lung cancer from smokers: review of mutations compiled in the IARC p53 database. , 1998, Environmental health perspectives.
[27] J. Huisman. The Netherlands , 1996, The Lancet.
[28] C. Croce,et al. The FHIT Gene at 3p14.2 Is Abnormal in Lung Cancer , 1996, Cell.
[29] A. Jemal,et al. Global Cancer Statistics , 2011 .
[30] C. Henschke,et al. Molecular characterization of small peripheral lung tumors based on the analysis of fine needle aspirates. , 2008, Histology and histopathology.
[31] S. Vicent,et al. Alpha CP-4, encoded by a putative tumor suppressor gene at 3p21, but not its alternative splice variant alpha CP-4a, is underexpressed in lung cancer. , 2004, Cancer Research.
[32] V. Somers,et al. Detection of K-ras point mutations in sputum from patients with adenocarcinoma of the lung by point-EXACCT. , 2003, Methods in molecular medicine.
[33] A. Jemal,et al. Global cancer statistics , 2011, CA: a cancer journal for clinicians.
[34] H. Hansen,et al. Lung cancer. , 1990, Cancer chemotherapy and biological response modifiers.